Drug companies are landing on the gem

Just after 2009, the disclosure of listed companies ' annual reports was immediately put on the agenda. Shenzhen January 3 issued "on the work of the 2009 annual report," asked the listed companies to disclose the 2009 annual report before April 30 this year, and the disclosure of the time not later than this year quarterly. Among them, the Enterprise board companies to make strict requirements, can not disclose the annual report of the Enterprise board companies will face temporary suspension and "exit risk warning" and other penalties.

The opening of the Gem is the 2009 China's capital market, one of the major events, including the first batch of the 6 pharmaceutical stocks are very eye-catching, red Sun pharmaceutical industry has been to 145.5 yuan, the recent week to stabilize the stock price of more than 90 yuan, the listing has been maintained at more than 80 times times. The second batch of gem is the only one of medicine, Yang Pu Medical, the trend is relatively stable, p/e multiples in 30~40 times.

Drug companies continue to land on the gem

Listed on December 25, 2009, YANGPU medical treatment, is a vacuum blood collection system industry leader, a total of 18.6 million shares issued, accounting for 25.14% of the total share capital after the issuance of 110 million yuan, to the modified medical polymer vacuum blood collection tube automatic production, VBCN one-time use of venous blood collection needle construction and biomedical engineering technology Research and Development Center construction 3 projects. Since the listing, YANGPU Medical stock has been maintained at 35 yuan up and down.

For YANGPU Medical, China Merchants Securities pharmaceutical researcher Xu Leihai that it has high growth. On the one hand, the third generation vacuum blood collection system of YANGPU medical main products is mainly used in blood specimen collection, pretreatment and analysis before the mutation control, its specimen analysis before the mutation control technology in the domestic leading position, its 2008 domestic market share of 8.3%, the global market share of 1%. On the other hand, the global vacuum blood collection tube market development potential is huge, and the Chinese market growth is faster: 2005-2008 years, the global vacuum blood collection tube sales growth of 8.3%, the Chinese market composite growth of 18%. The global vacuum tube market capacity is expected to accelerate in the next few years, the annual growth rate will reach about 10%, and 2009-2013 years China market demand composite growth rate will reach 20%.

In addition, YANGPU Medical services will pass FDA certification in the two quarter, into the global vacuum blood tube market 44% share of the U.S. market. Data show that YANGPU medical 2008 sales revenue and net profit of 103 million yuan and 20 million yuan respectively, year-on-year growth of 43% and 55%. China Merchants Securities is expected to increase the 2009-2011-year sales revenue of 31%, 43% and 46%, net profit will increase by 39%, 47% and 40% year-on-year.

Gem expansion has been a major trend, the Shenzhen stock market is intended to put more representative of a certain industry of high-quality entrepreneurial enterprises, so that the current focus on domestic capital markets, especially the gem has more space to release, but also can alleviate the current gem of many stocks of serious overdraft status. Gem of the third batch of Shanghai Kai Bao Pharmaceutical industry, began on December 24, 2009 online purchase, and Beijing Star Hao has been listed in the EIA stage before.

Venture capital institutions believe that the biggest problem of the development of enterprises is insufficient funds, and the biomedical industry, especially with high investment, high risk, high profits of the industry, many small and medium-sized pharmaceutical enterprises in the sustainable development of the need to finance through the IPO. And the opening of the gem, not only for the rapid withdrawal of VC provides a platform, but also for innovative small and medium-sized drug enterprises to solve the problem of funds to provide a smooth financing channels, is expected to have more qualified pharmaceutical enterprises in the future of the gem.

Performance Advance is guaranteed

Among the first 28 listed companies in the Gem, le Pu medical, ai er, North Land Medicine, Leme Biology, and the Red Sun Pharmaceutical industry 6 pharmaceutical enterprises are private enterprises, from the existing business and fundamental situation, 6 companies in their respective subdivision areas with a certain degree of industry status and advantages, 2008 average income of 270 million yuan, net profit scale of 70.1 million.

According to the requirements of CSRC and Shenzhen, the disclosure time of 2009 Annual report of GEM listed companies will be concentrated in this March. A number of securities research institutions on the Gem pharmaceutical company performance Prediction results are better, especially in the 2009 ~2010 years, for the new health reform implementation of the initial stage, during which the quality of a certain industry representative enterprises will be able to achieve a relatively rapid growth.

Red Sun Pharmaceutical Industry recently said that the 2009 annual report will be released on March 18. Data show that up to the first three quarters of 2009, the Red Sun medicine to achieve sales revenue of 140 million yuan, net profit of 52 million yuan. Galactic Securities and pharmaceutical researcher Li Hupeng that the short-term growth of the red Sun pharmaceutical industry still comes from the two leading products of blood will be net and hydrochloric acid, and with the coverage of hospital coverage, potential patients and the effect of academic promotion, its sales revenue will continue to grow.

Leona Peng Forecast, Red Sun Pharmaceutical industry 2009-2011 years of main business income is 232 million yuan, 288 million yuan and 358 million yuan, net profit is 80.9 million yuan, 105.43 million yuan and 134.12 million yuan respectively.

Another 5 gem 2009-year performance is also bullish, the rapid growth of its main business is a certainty, most of this year in March to produce a bright annual report. Moreover, after "absorbing gold", the gem company will gradually use the funds to expand its main business, which will be beneficial to their future development.

However, it is noteworthy that most securities research institutions still believe that the gem is currently overvalued, especially in the first batch of 28 companies, stock prices may have been heavily overdrawn. After the second batch and the third batch of the Spring festival gradually listed, investors for the first batch of heat will likely reduce. As more companies enter the gem, the valuation of the gem will gradually move towards rationality.